Estimated read time: 3-4 minutes
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
WASHINGTON — The Biden administration on Tuesday released its list of 10 prescription medicines that will be subject to the first-ever price negotiations by the U.S. Medicare health program that covers 66 million people, with big-selling blood thinner Eliquis from Bristol Myers Squibb and Pfizer among them.
President Joe Biden's signature Inflation Reduction Act, signed into law last year, allows the Medicare health program for Americans aged 65 and over to negotiate prices for some of its most costly drugs.
"There is no reason why Americans should be forced to pay more than any developed nation for life-saving prescriptions just to pad Big Pharma's pockets," Biden said in a statement.
He said that once implemented, the prices on negotiated drugs will decrease for up to 9 million seniors who currently pay as much as $6,497 in out-of-pocket costs per year for these prescriptions.
Medicines on the list include Merck & Co's diabetes drug Januvia, Eliquis rival Xarelto from Johnson & Johnson, and AbbVie's leukemia treatment Imbruvica.
Other drugs on the list include Amgen's rheumatoid arthritis drug Enbrel, Boehringer Ingelheim and Eli Lilly's diabetes drug Jardiance, J&J's arthritis and Crohn's disease Stelara and insulin from Novo Nordisk.
Shares of drugmakers were mostly flat in premarket trading.
This kicks off the negotiation process for the 10 drugs whose new prices will go into effect in 2026. The program aims to save $25 billion per year on drug prices by 2031.
U.S. laws had prohibited the Medicare drug program from negotiating pharmaceutical prices as part of its prescription drug program that began about 20 years ago.
There is no reason why Americans should be forced to pay more than any developed nation for life-saving prescriptions just to pad Big Pharma's pockets.
–Pres. Joe Biden
The U.S. Centers for Medicare and Medicaid Services spent $50.5 billion between June 1, 2022, and May 31, 2023, on the 10 drugs, which is the time period used to determine which drugs were eligible for negotiation. That was about 20% of the total cost of drugs in the Medicare prescription drug program known as Part D.
Wells Fargo analyst Mohit Bansal said the savings made from negotiations on Jardiance, Januvia, Farxiga and Insulin Aspart, which cost the agency about $16.5 billion, could potentially free up the center's budget and make it easier to cover diabetes or obesity drugs.
Pharmaceutical Research and Manufacturers of America, the industry lobby, said many of the medicines on the list are already subject to significant discounts through private market negotiations.
Drugmakers including Bristol Myers, Johnson & Johnson, Merck, Britain's AstraZeneca, and Germany-based Boehringer Ingelheim have also sued the U.S. Department of Health and Human Services, which oversees the Medicare agency, in an effort to derail the price-setting process.
Americans pay more for prescription drugs than patients in all other developed nations. Under the program, the minimum cut from a drug's list price will be 25%, but the government could barter for much bigger discounts.
Now that the list is out, drugmakers will have until Oct. 1 to sign agreements to participate in talks and until Oct. 2 to submit data on their medicines, including research and development and production costs, information on patent applications and revenue and sales volume.
Unless it is blocked by a court, the Medicare agency will publish the new agreed prices on Sept. 1, 2024.
